Amalgamated Bank Has $90,000 Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Amalgamated Bank increased its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 22.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,840 shares of the company’s stock after buying an additional 530 shares during the quarter. Amalgamated Bank’s holdings in IDEAYA Biosciences were worth $90,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Allworth Financial LP lifted its position in shares of IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock worth $29,000 after buying an additional 800 shares during the period. Quest Partners LLC bought a new position in shares of IDEAYA Biosciences during the 2nd quarter worth approximately $41,000. Covestor Ltd raised its position in IDEAYA Biosciences by 9,225.0% in the 1st quarter. Covestor Ltd now owns 1,119 shares of the company’s stock valued at $49,000 after purchasing an additional 1,107 shares during the last quarter. US Bancorp DE raised its position in IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after purchasing an additional 689 shares during the last quarter. Finally, Comerica Bank raised its position in IDEAYA Biosciences by 723.5% in the 1st quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after purchasing an additional 1,324 shares during the last quarter. Institutional investors own 98.29% of the company’s stock.

Wall Street Analyst Weigh In

IDYA has been the subject of several research analyst reports. Citigroup cut their price objective on IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating for the company in a research report on Tuesday, August 27th. Lifesci Capital upgraded IDEAYA Biosciences to a “strong-buy” rating in a research report on Monday, July 29th. Leerink Partners downgraded IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $41.00 to $27.00 in a research report on Tuesday, November 5th. Cantor Fitzgerald initiated coverage on IDEAYA Biosciences in a research report on Tuesday, October 15th. They issued an “overweight” rating for the company. Finally, Oppenheimer reiterated an “outperform” rating and issued a $53.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IDEAYA Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $53.91.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $26.64 on Monday. IDEAYA Biosciences, Inc. has a one year low of $26.41 and a one year high of $47.74. The firm has a market cap of $2.30 billion, a P/E ratio of -11.43 and a beta of 0.86. The stock’s 50-day moving average is $31.42 and its 200-day moving average is $36.30.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same period in the prior year, the firm posted ($0.46) EPS. Equities analysts anticipate that IDEAYA Biosciences, Inc. will post -2.46 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.